An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease

NCT06497491 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Still's Disease Adult Onset

Interventions

BIOLOGICAL: GNR-086
BIOLOGICAL: Ilaris®

Sponsor

AO GENERIUM